What is the risk of retinal detachment in patients with lattice degeneration?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: July 29, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Risk of Retinal Detachment in Patients with Lattice Degeneration

Patients with lattice degeneration have a very low absolute risk of retinal detachment—only 0.7% to 1.08% of eyes develop clinical retinal detachment over long-term follow-up, and prophylactic treatment of asymptomatic lattice is not warranted in most cases. 1, 2

Baseline Risk Stratification

The overall risk depends critically on several factors that must be assessed together:

Low-Risk Patients (No Treatment Needed)

  • Atrophic round holes within lattice lesions with minimal or no subretinal fluid and no posterior vitreous detachment (PVD) carry extremely low risk 1
  • In a landmark 11-year prospective study of 423 eyes with lattice degeneration, only 3 eyes (0.7%) developed clinical retinal detachment 1, 2
  • Of 150 eyes with atrophic holes in lattice, only 2% progressed to clinical detachment—both in young myopic patients in their mid-20s 1

Moderate-Risk Patients (Close Monitoring)

  • Subclinical retinal detachments (subretinal fluid extending >1 disc diameter from holes in lattice) have low likelihood of progression with observation alone 1
  • These should be monitored for documented progression, increasing size, or new symptoms before considering treatment 1

High-Risk Patients (Treatment Indicated)

  • Symptomatic horseshoe tears associated with acute PVD: At least 50% progress to clinical retinal detachment without treatment 1
  • Treatment reduces this risk to <5% 1
  • Young myopic patients (especially >-5.0 diopters) with lattice and atrophic holes have extraordinarily high lifetime risk and require enhanced vigilance 3

Population-Level Context

Lattice degeneration is present in 6-8% of the general population and increases retinal detachment risk, but approximately 20-30% of all retinal detachments occur in patients with lattice degeneration 1. This means the vast majority of people with lattice never develop detachment.

The cumulative lifetime incidence by age 80 is:

  • 1.5% from atrophic holes (by age 40)
  • 3.6% from tractional tears (by age 80)
  • 5.3% combined risk (by age 80) 4

Critical Risk Modifiers

Type of Lattice Pattern Matters

  • Perivascular or radial lattice carries significantly higher risk than circumferential lattice 1
  • Radial lattice is associated with much higher rates of tears and detachment 1

Mechanism of Detachment

The key distinction is whether detachment occurs from:

  1. Atrophic holes without PVD: Very low risk, typically in young myopes, slowly progressive 1, 5
  2. Tractional tears from PVD: Higher risk, occurs when PVD induces horseshoe tear at lattice margins—these require immediate treatment 1

Additional Risk Factors That Compound Risk

  • High myopia (>-5.0 D): Dramatically increases lifetime risk 3
  • Age <60 years: Higher risk of delayed tears after PVD 6
  • History of RRD in fellow eye: 10% increased risk in second eye 1
  • Planned cataract surgery: Post-operative PVD development is the major risk factor, not the lattice itself 1

Management Algorithm

For Asymptomatic Lattice (with or without atrophic holes):

  • No prophylactic treatment in phakic, non-fellow eyes 2
  • Regular follow-up only for young myopes with holes to monitor for subclinical detachment progression 1
  • Patient education about PVD symptoms (flashes, floaters, peripheral visual field loss) 1

For Symptomatic Presentations:

  • Acute PVD with horseshoe tears: Immediate laser or cryotherapy treatment 1
  • Progressive subclinical detachment: Consider treatment when documented enlargement or symptoms develop 1

Special Circumstance—Fellow Eye After RRD:

Recent evidence suggests prophylactic treatment of lattice in the fellow eye after first-eye RRD significantly reduces risk from 41% to 17% over 5 years 7. This is the one scenario where prophylaxis may be justified, though the 2020 AAO guidelines predate this evidence.

Common Pitfalls to Avoid

  1. Over-treating asymptomatic lattice: The Cochrane review found no randomized controlled trial evidence supporting prophylactic treatment of asymptomatic lattice or breaks 1. Treatment may be unnecessary, ineffective, or harmful.

  2. Missing the anterior border: When treating symptomatic tears, inadequate treatment at the anterior border (where visualization is difficult) is the most common cause of failure 1

  3. False reassurance after initial PVD exam: 2% of patients with acute PVD and no initial tears develop delayed tears, particularly those with vitreous pigment, hemorrhage, or visible traction—these need re-examination within 6 weeks 1

  4. Ignoring long-term risk: 5-14% of patients develop additional breaks during long-term follow-up after initial break treatment 1

References

3
Research

The influence of refractive error and lattice degeneration on the incidence of retinal detachment.

Transactions of the American Ophthalmological Society, 1989

4
Research

Risk of retinal detachment in patients with lattice degeneration.

Japanese journal of ophthalmology, 1998

Related Questions

Do patients with retinal lattice degeneration have an increased risk of complications following cataract surgery?
Can scopolamine be used in patients with retinal lattice degeneration, particularly those with a history of myopia or at risk for retinal detachment?
What is the cause of lattice degeneration (a condition affecting the retina)?
What are the risk factors for posterior vitreous detachment and the additional risk factors that predict an unfavorable outcome?
Can individuals with retinal lattice degeneration participate in activities such as scuba diving (at 5 meters), motorcycle (MC) or karting, horseback riding, or soccer?
Should Prolia (denosumab) be started or continued while the patient is still receiving vancomycin for active Clostridioides difficile infection?
Is buspirone safe to use during pregnancy, and what are the recommendations regarding dosage and breastfeeding?
What is the likely cause and recommended treatment for a painful mid‑palm nodule with sharp radiating pain to multiple fingers that began a few months ago?
In a 77-year-old female presenting to the emergency department with hypertension and intermittent lightheadedness but otherwise asymptomatic, what emergency department workup should be ordered?
What is the appropriate lorazepam (Ativan) dose for an adult patient experiencing panic attacks?
What are the indications, dosing guidelines, and contraindications for using Isolyte P (balanced electrolyte solution) in adult patients?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.